MELANOCORTIN-4 RECEPTOR AGONISTS
Application
US20260092056A1
Kind: A1
Apr 02, 2026
Inventors
Seung Wan Kang, Hee Dong Park, Hee Dong Park, Su Jin Yeo, Hyun Seo Park, Ji Ho Hong, Hye Won Ahn, Eun Sil Choi
Abstract
The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.
CPC Classifications
C07D 413/14
A61P 3/04
Filing Date
2025-12-05
Application No.
19410552